CLOs on the Move

AbbVie Canada

www.abbvie.ca

 
We`re a company that takes on the toughest health challenges. But we do more than treat diseases—we aim to make a remarkable impact on people`s lives. We are AbbVie, a highly focused research-driven biopharmaceutical company. Our ~30,000 employees are scientists, researchers, communicators, manufacturing specialists and regulatory experts located around the globe. We come up with new approaches to addressing today`s health issues—from life-threatening illness to chronic conditions. We target specific difficult-to-cure diseases where we can leverage our core R&D expertise to advance science. We`re constantly working to create solutions that go beyond treating the illness to have a positive impact on patients` ...
  • Number of Employees: 5K-10K
  • Annual Revenue: > $1 Billion
  • www.abbvie.ca
  • 8401 Trans-Canada Highway
    Saint-Laurent, QC CAN H4S 1Z1
  • Phone: 514.906.9700

Executives

Name Title Contact Details

Similar Companies

Ultimed

Ultimed is a Saint Paul, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Medical Center Compounding

Medical Center Compounding is a Cleveland, TN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Capcium

Capcium is a value-add pharmaceutical grade manufacturer of softgel capsules and other novel delivery technologies that was born from a strong desire to transform the cannabis, pharmaceutical, nutraceutical, over the counter (OTC) and cosmetics industries by setting new standards in the development and manufacturing of finished consumer products.

Accugenix

Accugenix offers a fixed pricing structure based upon turnaround time requirements. Whether your isolates are routine or require immediate attention, we have the operational flexibility and capacity to meet your needs. We also offer volume pricing

Metabolic Solutions Development

Metabolic Solutions Development Company, LLC (MSDC) discovers and develops novel molecular targets and new therapeutics to treat metabolic diseases associated with age-related mitochondrial dysfunction, especially insulin resistance and type 2 diabetes. The company has raised nearly $55 million in support of the development of its novel therapeutic drugs, MSDC-0160 and MSDC-0602, which selectively modulate mitochondrial control of to important cellular activities, such as carbohydrate, lipid, and amino acid metabolism, that are out of balance in patients with type 2 diabetes. Such imbalances may also play a role in other diseases of aging such as Alzheimer’s disease and Parkinson’s disease, as well certain genetic diseases such as polycystic kidney disease.